Propafenona Arena 150mg Tablets Malta - English - Medicines Authority

propafenona arena 150mg tablets

s.c. arena group sa 31 stefan mihaileanu street, 1 st floor, ap. 1, bucharest, romania - propafenone hydrochloride - tablet - propafenone hydrochloride 150 mg - cardiac therapy

RYTMONORM 150 MG TABLETAS RECUBIERTAS Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

rytmonorm 150 mg tabletas recubiertas

abbott laboratories de mÉxico, s.a. de c.v. - clorhidrato de propafenona - clorhidrato de propafenona....150 mg

RYTMONORM 150MG TABLETAS RECUBIERTAS. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

rytmonorm 150mg tabletas recubiertas.

abbott laboratories de mexico, s.a. de c.v - clorhidrato de propafenona - clorhidrato de propafenona....150 mg

RYTMONORM 150 MG TABLETAS RECUBIERTAS Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

rytmonorm 150 mg tabletas recubiertas

abbott laboratories de mexico, s.a. de c.v - clorhidrato de propafenona - clorhidrato de propafenona....150,00 mg

PROPAFENONE- propafenone hydrochloride capsule, extended release United States - English - NLM (National Library of Medicine)

propafenone- propafenone hydrochloride capsule, extended release

rebel distributors corp - propafenone (unii: 68iqx3t69u) (propafenone - unii:68iqx3t69u) - propafenone 325 mg - propafenone extended release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease. the use of propafenone er capsules in patients with permanent atrial fibrillation or in patients exclusively with atrial flutter or psvt has not been evaluated. propafenone er capsules should not be used to control ventricular rate during atrial fibrillation. the effect of propafenone er capsules on mortality has not been determined (see black box warnings ). propafenone er capsules are contraindicated in the presence of congestive heart failure, cardiogenic shock, sinoatrial, atrioventricular and intraventricular disorders of impulse generation or conduction (e.g., sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker, bradycardia, marked hypotension, bronchospastic disorders, electrolyte imbalance, or hypersensitivity to the drug.